EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions

Toka Elemary, Mina Nicola, Mohamed E A Abdelrahim, Dalia Zaafar

Molecular Biology Reports · 2025

DOI: 10.1007/s11033-025-10458-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Biology Reports, 2025. Verfasst von Toka Elemary und 3 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacy Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt. Toka.Hesham@pharm.mti.edu.eg. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Cardiovascular Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 98 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients diagnosed with type 2 diabetes have an increased risk of developing cardiovascular complications. The researchers are currently working on understanding how to prevent these progressions from occurring. Since 2006, dipeptidyl-peptidase-4 inhibitors have been made available to patients as a relatively new treatment for diabetes. These substances inhibit the enzyme known as dipeptidyl peptidase-4 (DPP-4), which in turn increases the levels of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This results in an increase in the effectiveness of insulin release after meals, which in turn has a positive impact on glycemic control. Regarding the safety of this category of medication in the treatment of cardiovascular disorders, there have been a great deal of debates. Emerging research suggests that DPP-4 inhibitors could be useful in the treatment of a variety of cardiovascular conditions, including coronary atherosclerosis, heart failure, and hypertension, among others. In order to investigate the possibility of using dipeptidyl-peptidase-4 inhibitors as a treatment option for cardiovascular disease, the molecular pathways that are thought to be responsible for their cardioprotective effect will be clarifies throughout the course of this review.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dipeptidyl-Peptidase IV InhibitorsCardiovascular DiseasesHumansDiabetes Mellitus, Type 2Dipeptidyl Peptidase 4Glucagon-Like Peptide 1Gastric Inhibitory Polypeptide

Stichwörter der Autor:innen

AtherosclerosisBrain natriuretic peptideCardiovascular diseasesDPP-4 inhibitorsGlucagon like peptide-1

Substanzen

Dipeptidyl-Peptidase IV InhibitorsDipeptidyl Peptidase 4Glucagon-Like Peptide 1Gastric Inhibitory PolypeptideDPP4 protein, human

Autor:innen und Institutionen

  • Clinical Pharmacy Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt. Toka.Hesham@pharm.mti.edu.eg.
  • Clinical Pharmacy Department, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.

Zitieren

APA

Elemary, T., Nicola, M., Abdelrahim, M. E. A., & Zaafar, D. (2025). The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions. Molecular Biology Reports. https://doi.org/10.1007/s11033-025-10458-7

Vancouver

Elemary T, Nicola M, Abdelrahim MEA, Zaafar D. The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions. Molecular Biology Reports. 2025. doi:10.1007/s11033-025-10458-7

BibTeX
@article{Elemary2025,
  author = {Elemary, Toka and Nicola, Mina and Abdelrahim, Mohamed E A and Zaafar, Dalia},
  title = {The impact of DPP-4 inhibitors on cardiovascular disease treatment: a comprehensive review of current therapeutic strategies and future directions},
  journal = {Molecular Biology Reports},
  year = {2025},
  doi = {10.1007/s11033-025-10458-7}
}
Kostenlos starten →